Author

Marjolijn Duijvestein

UEG Education Webinar | Sustainability in Gastroenterology
UEG Education Webinar | Sustainability in Gastroenterology

Marjolijn Duijvestein  et al.

Management of pouch problems: Gastroenterology
Management of pouch problems: Gastroenterology

Marjolijn Duijvestein

BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Marjolijn Duijvestein  et al.

MESENTERIC SPARING VERSUS EXTENDED MESENTERECTOMY IN PRIMARY ILEOCOLIC RESECTION FOR ILEOCAECAL CROHN’S DISEASE (SPICY TRIAL): PRELIMINARY RESULTS OF AN INTERNATIONAL MULTICENTRE RANDOMISED CONTROLLED TRIAL
MESENTERIC SPARING VERSUS EXTENDED MESENTERECTOMY IN PRIMARY ILEOCOLIC RESECTION FOR ILEOCAECAL CROHN’S DISEASE (SPICY TRIAL): PRELIMINARY RESULTS OF AN INTERNATIONAL MULTICENTRE RANDOMISED CONTROLLED TRIAL

Marjolijn Duijvestein  et al.

NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY
NATURAL HISTORY OF RECURRENT CROHN'S DISEASE FOLLOWING ILEOCOLONIC RESECTION: A MULTICENTER RETROSPECTIVE CROSS-SECTIONAL COHORT STUDY

Marjolijn Duijvestein  et al.

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS
REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

Marjolijn Duijvestein  et al.

INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY
INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY

Marjolijn Duijvestein  et al.

IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Marjolijn Duijvestein  et al.

RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)
RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)

Marjolijn Duijvestein  et al.

TOWARDS A GREENER ENDOSCOPY ROOM: RECYCLING PLASTIC WASTE
TOWARDS A GREENER ENDOSCOPY ROOM: RECYCLING PLASTIC WASTE

Marjolijn Duijvestein  et al.

REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE
REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE

Marjolijn Duijvestein  et al.

MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL
MERCAPTOPURINE TREATMENT USING THERAPEUTIC DRUG MONITORING IS EFFECTIVE IN ULCERATIVE COLITIS: A PLACEBO-CONTROLLED RANDOMIZED TRIAL

Marjolijn Duijvestein  et al.

USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE
USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE

Marjolijn Duijvestein  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

Marjolijn Duijvestein  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Marjolijn Duijvestein  et al.

Item 1 - 15 / 15
1